EA
KALV

Emerald Acquisition’s KalVista Pharmaceuticals KALV Stock Holding History

Emerald Acquisition’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,699
Closed -$183K – 3013
2016
Q2 		$183K Buy
+19,699
New +$228K ﹤0.01% 2748

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.55B AUM 19.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's KALV Position: Q3 2016 in Review

Emerald Acquisition sold out of KalVista Pharmaceuticals (KALV) in Q3 2016, closing a stake of 19,699 shares — an estimated $183K sold.

Emerald Acquisition first reported a position in KALV in Q2 2016 and held it in 1 quarter. The position peaked at $183K in Q2 2016. 21 funds tracked by Wall St. Rank hold KALV as of Q3 2016.

  • Emerald Acquisition reported no remaining KalVista Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 19,699 KalVista Pharmaceuticals shares in Q3 2016, an estimated $183K.
  • Emerald Acquisition first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's KalVista Pharmaceuticals position peaked at $183K in Q2 2016.
  • 21 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.